Immuno-Oncologist, Chief of Translational Research & Immuno-Oncology, Cedars-Sinai The Angeles Clinic and Research Institute, California, USA
Omid Hamid is the Chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, in Los Angeles, California, USA, where he serves as the Co-Director of the Melanoma and Director of Phase I Programs. His areas of expertise include immunotherapy and phase I drug development. He is recognized as one of the pre-eminent immuno-oncologists and melanoma specialists in the world, and has published extensively on and been at the forefront of paradigm-shifting breakthrough treatments, including BRAF/MEK-targeted agents, anti-CTLA4, anti-PD-1 and anti-PD-L1 therapies. His current research interests include next-generation immunotherapeutics, including novel immune-checkpoint inhibitors, bispecific antibodies, adoptive T cell therapies and oncolytic therapies, with a focus on combinatorial approaches.
Associate Professor, Radiation-Oncologist, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Iran
Farzad Vaghef Davari
Assistant Professor of Surgery, Fellowship of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Iran
Assistant Professor of Hematology & Oncology, School of Medicine, Research Center for Cancer Screening & Epidemiology, AJA University of Medical Sciences, Iran
Associate Professor, Research Institute for Oncology, Hematology and Cell Therapy, Head of Leading House for Iran-North America Academic Partnerships, Tehran University of Medical Sciences, Iran